Original news and analysis on international IP policy
KAMPALA, UGANDA - In light of the persistence of the Ebola outbreak and the demands it has placed on global infection containment resources and processes, the United States government disaster response community recognised an opportunity to use open innovation to make significant strides in advancing the ability to combat Ebola. The results include a local success story.
NEW YORK - Will generics companies use a win under the new inter partes review mechanism in the United States to overturn pharmaceutical patents in court? A top attorney for a pharmaceutical innovator company says they could indeed. Meanwhile, a new analysis of the inter partes review so far shows it may not be as much of a cause for alarm as previously thought.
Efforts to revamp protection for and enforcement of intellectual property rights in non-EU countries are welcome, but the European Commission should get Europe's IPR house in order first, a new draft report by the European Parliament International Trade (INTA) Committee says. Meanwhile, internal IPR reform is advancing on several fronts, said the EC, which gave Intellectual Property Watch an update on the various measures.
For international trade, 2015 will be “a year of work” rather than of finalisation, as Viviane Reding put it. The comment of the former European Commission vice president and Justice Commissioner focussed on the Trade in Services Agreement (TISA), as she is now the European Parliament's rapporteur for TISA. The services agreement is still sailing under the radar compared to its bigger cousins, the US-EU bilateral Transatlantic Trade and Investment Partnership (TTIP) and the Trans-Pacific Partnership Agreement (TPP). Yet “a year of work” might well describe the 2015 agenda for the mega-regional trade negotiations too. Will any of them get to the finish line? A race is on in which the United States and European Union seem to anxiously look to China's advance while fighting rising opposition at home.
An initiative spearheaded by the Global Fund for AIDS, Tuberculosis and Malaria to ensure equitable access to medicines in particular in middle-income countries now has a dedicated webpage publishing the terms of reference of the initiative. Also available is the list of high-level participants who attended the first meeting of the initiative held last week.
Ellen 't Hoen writes: On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request for an extension of the transitional period under article 66.1 TRIPS with respect to pharmaceutical products until the country is no longer classified as LDC.[1] The original extension, set to expire on 1st January 2016, specifically removes the obligation for LDCs to comply with Section 5 (Patents) and Section 7 (Protection of Undisclosed Information) of Part II of TRIPS, including any obligation to enforce rights under these provisions.
It is a little known fact that since the adoption of the 2001 Doha Declaration on TRIPS and Public Health, LDCs have frequently used the extension in day-to-day procurement of low cost generic medicines, in particular to access medicines needed for the treatment of HIV.
According to an internal report of the United Nations Development Programme (UNDP) Global Fund Partnership team, the Ebola epidemic has virtually halted national HIV efforts in Sierra Leone. In particular, patients stopped their treatments and the supply chain was disrupted.
This week a confidential high-level expert meeting was convened in Geneva to start work on a potential change in the country classification used by global health actors to remedy the growing problem of access to medicines in middle-income countries.
Last week’s 2015 Social Forum led by the UN Office of the High Commissioner for Human Rights (OHCHR) called for urgent action to facilitate access to medicines. In particular, the functioning of the intellectual property system was put into question. A number of recommendations were drawn by the secretariat after having been identified by participants.
NEUCHATEL - Switzerland is among the best students of global innovation. It continues to score at the top of global indexes and reports on innovation and competitiveness. At a seminar last week at the University of Neuchâtel, speakers gave their views on that success.